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Abstract
Therapeutic strategies are being clinically tested either to eradicate the latent HIV reservoir or to
achieve virologic control in the absence of antiretroviral therapy (ART). Attaining this goal will
require a consensus on how best to measure the levels of persistently-infected cells with the
potential to cause viral rebound upon ART cessation to assess the results of cure-directed
strategies in vivo. Current measurements assess different aspects of the HIV provirus and its
functionality, and produce divergent results. Here, we provide the collective insight and position
from the BEAT-HIV Martin Delaney Collaboratory on which viral measurements to prioritize in
HIV cure-directed clinical trials.
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Antiretroviral therapy (ART) has dramatically reduced morbidity and mortality for people
living with HIV (PWH) by effectively suppressing viral replication to undetectable levels in
plasma.1–4 However, ART requires lifelong administration and does not eradicate HIV,
which continues to cause immune activation, chronic inflammation, and ongoing damage to
multiple organs systems.5–8 Therefore, effective therapeutic strategies are needed to cure
HIV infection.

Author Manuscript

The main obstacle to cure HIV is that the virus establishes stable reservoirs of persistentlyinfected cells, in blood and different anatomical sites.9 These reservoirs persist despite longterm ART and can be broadly divided into two groups. The “latent reservoir” in which cells
carry an integrated copy of the viral genome that does not express viral transcripts or
proteins. These latent proviruses are not affected by ART or cleared by the immune system;
however, they can revert to a viral productive state upon stimulation.10–12 In addition to the
latent reservoir, the active reservoir is a minor population of transcriptionally-active cells,
producing HIV RNA/proteins and possibly virions, that can be detected in PWH despite
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long-term ART. Targeting and eliminating both types of reservoirs is the focus of the quest
for an HIV cure.13
Currently, several clinical trials are being conducted to evaluate the impact of potential
therapeutic strategies to cure HIV. The success of these trials hinges on the ability to
measure the size of HIV reservoirs before and after such interventions as a guide to ART
interruption. However, there is no consensus on how to use the variety of assays currently
available to evaluate the size of HIV reservoirs with the potential to cause viral rebound in
the absence of ART. In this Perspective, we provide our collective view on which viral
measurements to prioritize in HIV cure-directed clinical trials (Figure 1).

Challenges to measuring the HIV reservoir
Author Manuscript

There are four major challenges facing clinical trial design when measuring changes in HIV
reservoir size on ART: the vast majority of proviruses persisting in ART-treated PWH harbor
mutations and/or deletions rendering them defective and unable to replicate; not all intact
genomes (genomes with no defective mutations/deletions) are inducible to produce virions;
the frequency of latently-infected cells is very low; and the vast majority of HIV reservoirs
are in tissues that cannot be accurately sampled with current specimen collection
approaches.14–20

Author Manuscript

HIV cure-directed studies in ART-suppressed PWH currently measure levels of total proviral
DNA, intact provirus, transcriptionally-competent provirus (viral RNA), translationallycompetent provirus (protein), and replication-competent virus. These clinical studies
primarily measure changes in the aforementioned viral measures using four specimen types:
peripheral blood mononuclear cells (PBMCs) obtained either by phlebotomy or
leukapheresis, and biopsies from gut-associated lymphoid tissue (GALT) or lymph nodes
(LN). It’s probable that no measurement of a single compartment can fully inform on the
totality of reservoir dynamics under ART. Most clinical trial designs mainly collect
peripheral blood for the ease of longitudinal sampling, the willingness of participants to
donate blood frequently, its low cost, high throughput, and ease of collection at clinical sites
around the world. As mentioned, GALT and LN biopsies are also collected in some clinical
trials. While, HIV might persist in other tissues, the collection of these other tissues is
challenging.

Measuring levels of replication-competent virus or intact HIV genomes
Quantitative viral outgrowth assay (QVOA) and its derivates

Author Manuscript

Until recently, the QVOA and its derivatives (see Table 1) were the standard measurements
of the replication-competent HIV reservoir.21,22 However, we think that QVOA is not well
suited for cure-directed studies due to its high cost, labor requirements, need for a high
number of cells (limiting its use to peripheral blood cells), and biosafety containment
requirements. Moreover, QVOA underestimates the size of the replication-competent viral
reservoir, as not all intact HIV proviruses can be induced to release virus following a single
round of T cell activation.20,23
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Other assays have been developed based on QVOA, such as Q2VOA. Q2VOA has the same
limitations of QVOA in under-estimating reservoir size; however, it provides added
sequence information in addition to an estimate of reservoir size.24 Independently from
QVOA or other similar outgrowth-based assays, single-genome, near full-length proviral
sequencing does allow for a detailed analysis of the proviral landscape such as an ability to
identify the frequency of intact and defective proviral species, phylogenetic sequence
analysis and detection of clonal intact proviral sequences.19,20,25,26 However, near fulllength proviral sequencing is laborious and time-intensive, rendering it unfeasible for large
HIV cure-directed clinical trials. In addition, methods relying on long-distance PCR may not
be highly quantitative due to the possible inefficiency of such reactions.
Emerging PCR-based techniques to measure intact HIV DNA levels

Author Manuscript
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The above limitations prompted the development of more sensitive and straightforward
assays to distinguish between intact and defective proviruses. New assays, including the
intact proviral DNA assay (IPDA),27 and the Quadruplex qPCR (Q4PCR) assay,28 now offer
promising strategies that require a relatively small number of cells to estimate the size of
genetically-intact HIV populations in a labor and cost-effective manner, when compared to
QVOA or near full-length HIV provirus genome sequencing. Based on the specific
requirements of these two assays, we think that IPDA is best suited for high-throughput
analysis of large interventional or observational clinical studies; for instance, a recent
longitudinal cohort analysis evaluated the decay rate of intact and defective proviruses in a
large cohort of patients using IPDA.29 However, these studies have also revealed that <2% of
estimated intact proviruses are expected to be induced ex vivo. This observation raises the
question whether we would also need to add an inducibility index to IPDA measures as
defined by a concurrent viral outgrowth assays (discussed below) to define the relative
frequency of cells producing replication-competent virus.30 On the other hand, the Q4PCR
assay interrogates four regions of the genome after a near-full-length PCR, providing more
detailed information on proviral integrity and direct confirmation of viral sequences. These
added steps in Q4PCR may provide valuable information in smaller trials or trial designs
where viral sequencing is important, but near full-length sequencing is prohibitively costly
or time-consuming. For example, HIV cure-directed studies that use a lentiviral vector as a
delivery mechanism such as the CD4 CAR (NCT03617198) may best be served by the
Q4PCR assay to distinguish between circulating HIV and lentiviral vector sequences.

Author Manuscript

While these two newer assays are promising, future studies are needed to: validate them in
large independent cohorts; perform blinded comparisons between laboratories; assess
relationship with induction potential; and establish if levels of intact proviral HIV DNA in
the blood and/or tissues correlate with time to or magnitude of viral rebound during an
analytical treatment interruption (ATI). As with any sequence-based assay, sequence
polymorphisms preclude amplification in a fraction of PWH and may require alternative
primer/probe sets. It will be critical to validate the ability of the primer/probe sets used in
these assays to overcome the intra- and inter-individual diversity in HIV sequences. This
also includes validating these assays among different HIV clades as most studies to date
have been performed in regions with dominant clade B. Importantly, these assays can be
performed on frozen cells; therefore, we suggest storing of samples from clinical trials until
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adequate validation of these assays is completed. With regards to the future use of these
assays using GALT biopsies, we currently recommend the analysis of ileum tissue due to
higher lymphocyte-rich regions, and the pre-enrichment of CD45+ leukocytes as it has been
shown that this step increases the sensitivity of detecting persistent HIV measures.31,32
The murine viral outgrowth assay (mVOA)

Author Manuscript

mVOA, in which large numbers of cells from PWH can be adoptively transferred to NSG
[immunodeficient non-obese diabetic (NOD)] mice and monitored for viremia, represents
another tool to assess levels of replication-competent HIV proviruses.33,34 This assay may
be more sensitive than traditional ex vivo outgrowth assays in detecting replicationcompetent HIV from PWH with very low to undetectable levels of HIV DNA and RNA in
peripheral blood mononuclear cell (PBMC), due to the in vivo setting.33,34 This assay, by
testing a large number of cells in an in vivo environment that may support amplification over
time, maybe useful for confirming the absence of replication-competent cells when (1) no
other assays detect infectious virus or intact provirus, and (2) no ATI is included in the trial
design. However, it is important to note that this assay is laborious, costly, and timeconsuming.
HIV integration sites analysis
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It is also possible to measure the distribution of HIV DNA integration sites in PWH samples,
which can provide information on reservoir structure and maintenance. Quantitative
understanding of HIV integration sites can identify HIV-infected cells which are
preferentially proliferated in vivo. Understanding why certain HIV-infected cells
preferentially proliferate in vivo can provide important information for prioritizing the
elimination strategies targeting the proliferating HIV latent reservoir, a current major
challenge in the HIV cure field. Second, integration site data may also be linked to studies of
provirus inducibility.35,36 For example, HIV is known to favor integration in active
transcription units, and associated features,37,38 and this may influence subsequent proviral
gene activity.39,40 Finding ways to target proviruses that are not readily induced may be key
to reaching ART-free viral control (functional cure). An integrative understanding of HIV
integration site and proviral genome integrity (by using MIP-seq39 or MDA-SGS41) or HIV
integration site and HIV-driven aberrant cancer gene expression (by using HIV SortSeq42)
may provide new therapeutic insights into targeting intact and inducible HIV reservoirs. This
level of analysis requires a large number of cells (i.e., leukapheresis) and a high investment
(labor and cost) per study participant analyzed.

Author Manuscript

The BEAT-HIV Collaboratory position on assays measuring the amount of putative intact
HIV proviral genomes is to give priority to either the IPDA or Q4PCR approach using both
blood and tissue samples (pending validation; Figure 1) when assessing the success of a
potential curative strategy in targeting the levels of intact HIV DNA. When cell numbers
allow and undetectable levels of HIV are noted in trial designs that do not include a
treatment interruption phase to assess viral rebound after ART interruption, the inclusion of
mVOA (for understanding inducible reservoirs) and MIP-Seq (for more in-depth qualitative
insights on viral sequences) on a limited subgroup of clinical trial participants should be
considered.
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Measuring levels of translationally-competent virus
Studying cellular reservoirs capable of producing HIV antigen, e.g., gag p24 protein, is
biologically and scientifically relevant as protein is more likely, compared to RNA
transcripts, to trigger innate and adaptive immune responses, lead to persistent immune
activation, and play a role in HIV pathogenesis. HIV antigen is also the target of several
immune-based curative strategies.43,44 Furthermore, since viral protein production requires
intact viral reading frames, viral protein detection would be expected to identify inducible
proviruses relatively frequently, albeit not always as defective proviruses can also express
viral proteins.20,45,46 Thus, evaluating the translational competency of HIV reservoirs (latent
or active) complements measures of genetically intact, replication-competent virus.
Digital p24 Single Molecule Assay Technology (SIMOA) immunoassay

Author Manuscript
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Current protein-based measurements take advantage of the natural amplification provided by
the high number of HIV gag molecules generated per cell or per virion, together with
emerging ultra-sensitive methods for protein detection. The enhanced digital p24 SIMOA
immunoassay provides rapid and direct quantification of viral antigen from single HIV+ cell
in the absence or presence of CD4+ T cell stimulation (i.e., steady-state or inducible
reservoirs, respectively).43,47–50 Advantages of this assay include measurement of virus with
sufficient genetic integrity to drive transcription, translation, and downstream processing,
however, this approach will likely overestimate the size of the replication-competent
reservoir as the increased sensitivity of this assay may allow detection of virion production
by cells harboring replication-defective proviruses (e.g., a provirus with packaging signal
deletions).20,46 In all outgrowth assays, a failure to document exponential increases in viral
RNA or protein over time in culture may contribute to an over-estimation of reservoirs if
only measured by ultra-sensitive p24 SIMOA.51–53
Induced cell-associated p24 quantification may also inform on the relationships between
HIV persistence and immunological responses as translational-competent cells may
contribute to chronic inflammation and immune activation during ART. Lastly, the digital
p24 SIMOA assay requires a small number of cells and is applicable to a variety of
specimens from various anatomical compartments (blood or tissue). Therefore, our
collective recommendation is to include the induced p24 expression as measured by the
SIMOA immunoassay (Induced p24/SIMOA) as one of the primary readouts for quantifying
levels of steady-state/inducible translationally-competent virus in blood and/or tissues
during HIV cure-directed clinical trials (Figure 1).
Single-cell FISH-flow cytometry and other assays measure translationally-competent virus
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Apart from the induced p24/SIMOA assay, assessments of induced p24 expression can also
be performed using live cells by single-cell FISH-flow cytometry allowing for the added
assessment of the frequency of infected cells.54–56 Other assays of the translationallycompetent virus, such as ultrasensitive QVOA p24 SIMOA (measuring p24) or QVOA
cfRNA (measuring cell-free HIV RNA; a surrogate of HIV virions produced upon ex vivo
stimulation of resting CD4+ T cells) have been developed using a limiting dilution step of
input cells.57–59 Compared to the QVOA, flow cytometry-based assays are simpler, have
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higher throughput and sensitivity, and require few cells. However, in contrast to the QVOA,
they measure the frequency of cells that are inducible ex vivo to produce viral virions and/or
HIV protein [whether harboring defective or replication-competent (intact) virus]. Further
studies are needed to evaluate whether the measurements from any of these assays
measuring the levels of translationally-competent provirus can reflect the dynamics of an
ATI viral rebound in vivo.

Author Manuscript

The BEAT-HIV Collaboratory position on assays measuring the amount of translationallycompetent virus is to give priority to direct p24 immunoassay quantification (either without
stimulation or following short ex vivo stimulation to reactivate virus without expansion)
followed by measuring changes in inducible infected cell frequency by QVOA cfRNA or
QVOA p24 SIMOA (measuring frequency of cells producing virions or viral proteins
followed ex vivo stimulation and expansion) (Figure 1). It is important to note that it remains
undetermined how different stimuli or repeated stimulations may affect the reactivation
potential of different infected cells to express p24, therefore, stimuli used and limitations of
each assay should be carefully considered.60

Measuring levels of transcriptionally-competent virus

Author Manuscript

Viral RNA assays have been used broadly to measure both productive infection and latency
reversal; however, given that >90% of proviral DNA is defective, these measures
overestimate the size of the reservoir capable of producing infectious virions and are
inadequate for determining the effectiveness of interventions targeting translationally- or
replication-competent reservoirs.19,20,27 In contrast, measuring cell-associated HIV RNA
transcripts that persist during ART (total, elongated, unspliced, polyadenylated, and multispliced) or the ratio of HIV RNA to HIV DNA might indicate the degree of HIV residual
transcriptional activity.59,61–63 These measures could provide an early indication of change
following therapeutic interventions that aim to either stimulate or block viral transcription.
Such assays provide 1–2 log10 greater sensitivity over assays of intact or replicationcompetent virus by providing a greater dynamic range to measure the impact of an effective
intervention. Moreover, transcriptionally-competent HIV infected cells may be a significant
contributor to chronic inflammation and immune activation during ART, which could impact
the efficacy of curative strategies. Importantly, levels of cell-associated HIV RNA during
ART (both unspliced and multi-spliced) can serve as predictors of viral rebound after
therapy interruption,64,65 supporting the biological and clinical relevance of these HIV RNA
measures in measuring the size of HIV reservoirs.
TILDA and HIV-RNAscope

Author Manuscript

It should be noted that qPCR and droplet digital PCR assays measuring levels of HIV
transcripts without a serial dilution step of input cells only evaluate the levels of HIV RNA
in bulk cells, but do not determine the frequency of cells that are transcriptionallycompetent. Characterizing the frequency of transcriptionally-competent cells before and
after interventions can be an important parameter, especially in the context of clinical
interventions expected to eliminate cells that are HIV transcriptionally active. If HIV RNA+
cell frequency is needed, we suggest the inclusion qPCR and droplet digital PCR assays
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measuring levels of HIV transcripts with a serial dilution step of input cells, such as the
Tat/Rev Induced Limiting Dilution Assay (TILDA) 66 or similar assays 59 (Figure 1). In
addition, measuring levels of residual viremia may be useful when evaluating strategies
aimed to reactivate the latent reservoir (shock and kill strategies). However, in the absence of
a reactivation strategy, the dynamic range of assays measuring residual plasma HIV RNA
after ART limits the use of this assay in cure-directed study design67–69. Finally, for tissuebased specimens, direct in situ hybridization-based assays, such as HIV-DNAscope and
HIV-RNAscope, have high priority, as isolation of substantial numbers of CD4+ T cells and
macrophages from biopsies may be difficult. These assays provide an important spatial
context of HIV reservoirs as well as an understanding of the microenvironments/cellular
immune neighborhoods in which HIV RNA+ and DNA+ reservoirs reside within tissue (i.e.,
providing a superior understanding of the cellular distribution, the phenotype and
transcriptional state of persistently infected cells in vivo).53,70,71 However, the ability of
these assays to quantify total tissue reservoirs is unknown and unlikely considering the
limited tissue sampling available from participants in a clinical trial.
The BEAT-HIV Collaboratory position on assays measuring the amount of transcriptionallycompetent virus is to give priority to the use of RNA (and DNA)-scope (when using tissue
specimens) assays to be followed by levels of HIV transcripts and the frequency of HIV
transcriptionally competent cells, particularly if the strategy is expected to stimulate or block
HIV transcription.

Measuring total and integrated levels of HIV DNA
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Reservoir size has been characterized by PCR quantification of the total, integrated, and
episomal HIV DNA. Interpretation of these measures is complicated by the differential
decay rates of HIV DNA and the fact that the vast majority of proviral DNA is profoundly
defective.19,20,27 Despite this limitation, total HIV DNA has been measured in many settings
and provided important insights on HIV persistence.53,72–76 In addition, measuring total
HIV DNA levels could be the only assay possible when a limited cell number is available as
other assays might not be sensitive enough for quantitative measurement. In addition to
levels of total HIV DNA, specific assays have been developed to measure integrated HIV
DNA and episomal HIV DNA (2-LTR circles). Since post-integration latency is thought to
represent the major form of viral persistence, levels of integrated HIV DNA provide a more
accurate measure of HIV reservoir size than total HIV DNA and in steady-state conditions
are correlated with IPDA measures.77 Integrated HIV DNA assays require either a pre-PCR
separation of high molecular weight DNA78 or a pre-amplification step with primers for
genomic Alu elements and HIV sequences.72,79–81 In summary, based on the goal of curedirected studies to detect a change in replication-competent provirus and availability of
assays such as IPDA or Q4PCR that are able to estimate a change in putative intact HIV
provirus numbers irrespective of total HIV DNA with predominant defective proviruses, it is
our collective view to place a lower priority for measuring levels of integrated HIV DNA in
clinical trials unless available cell number is limited (Figure 1).
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Sources of cells

Author Manuscript

HIV latency has been extensively characterized in resting CD4+ T cells, which typically do
not produce virions or viral antigens ex vivo before activation by a latency-reversing agent.12
HIV can also be detected in cells expressing classical activation markers such as HLA-DR.
12,53,82 However, the extent to which a steady-state of activated infected CD4+ T cells
contribute to HIV persistence during ART remains unknown as these cells are expected to
have a short half-life by expressing viral antigens exposing these cells to viral cytopathic
effects and/or immune clearance. HIV has also been detected in different memory cell
subsets.83 It is important to note that recent studies show that the markers used to define
memory cell populations change with activation state and that intact proviruses are found in
most if not all T cell subsets.30,56,83 For example, naïve CD4+ T cells can harbor a small but
significant portion of HIV replication-competent virus in vivo.84 Given the absence of a
single marker that can identify latently infected CD4+ T cells, and the wide distribution of
the reservoir between T cell subsets, we suggest performing the aforementioned measures
first on total CD4+ T cells. Analysis of total CD4+ T cells would more accurately reflect the
steady-state of HIV persistence, with the caveat that virus detected may originate from both
latently-infected cells and recently activated CD4+ T cells (latent and active reservoirs).
When larger quantities of CD4+ T cell are available, as in the case of leukapheresis or lymph
node biopsy, measurements can be performed on different CD4+ T cell subsets,83 including
resting, naïve, central memory, effector memory, follicular helper CD4+ T cells, resident
memory CD4+ T cells, regulatory T cells, and other relevant cell populations.

Author Manuscript

Finally, we acknowledge that CD4+ T cells may not constitute the sole viral reservoir in vivo
as other cellular compartments such as tissue-resident myeloid cells may harbor persistent
HIV after ART.85,86 However, the difficulty in isolating myeloid cells from tissue
compartments limits the analysis of these cell types to in situ hybridization approaches (i.e.,
HIV-DNAscope and HIV-RNAscope) and non-human primates. Therefore, our current
inability to account for the potential retention of persistent HIV in myeloid subsets after
ART highlights a gap in our ability to monitor this compartment in clinical trial design.
Finally, rapid autopsies are useful to obtain viable deep tissues from PWH on ART
participating at the end of life studies, but they are likely not useful in interpreting change in
reservoirs after an intervention as an autopsy provides a one-time measurement.87

Host surrogates of reservoir size

Author Manuscript

To gain insight into the host pressures that control HIV persistence, latency and reactivation,
a comprehensive examination of host factors and cell subsets contributing to viral outgrowth
ex vivo and rebound viruses in vivo after an ATI is needed. Regarding host factors, rebound
HIV isolates after an ATI, but not those activated to by outgrowth ex vivo in a QVOA, are
uniformly resistant to the antiviral activities of type 1 interferons (IFN-I). This observation
indicates that tissue-specific innate responses limit the viruses that successfully reactivate
from latency.88 Phenotypic analyses of QVOA and rebound isolates, including a comparison
of their replicative fitness, cell tropism, glycosylation changes, and neutralization sensitivity
can provide further insight into the host factors that maintain the latent HIV reservoir and
may allow tracking the provenance of the rebounding virus.89 In addition to the phenotypic
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analyses of QVOA and rebound, several studies have shown associations between host
immune-related factors and HIV persistence during ART. Cell surface expression of negative
immune checkpoints (PD-1, TIGIT, and LAG-3) correlates with levels of HIV DNA and
RNA during ART.90–92 The expression of select anti-HIV host restriction factors are also
associated with levels of cell-associated HIV RNA during ART.93 Levels of anti-HIV
antibodies can reflect both the degree of HIV persistence and low-level viral replication.
94–96 While we have focused this perspective on virological measurements of persistent HIV
reservoir, it is our view that concurrent measures of host factors associated with changes in
viral reservoirs or rebound could be a critical component in understating the impact of
potential interventions on the totality of the body’s HIV reservoirs during a cure-directed
trial.

Analytical Treatment Interruptions (ATI)
Author Manuscript
Author Manuscript

The likelihood of rebound is thought to be a function of both the size of the inducible
replication-competent reservoir and the strength of the immune responses. Clinical data have
as yet failed to reveal a threshold of the number of the virus measured while ARTsuppressed by any laboratory viral assay below which rebound will not occur.34,97 The
inability of viral measures alone to predict a lack of rebound may reflect the absence of
taking into account host immune measures. With regards to viral measures alone, modeling
studies suggest that a very large reduction in the replication-competent virus levels would be
needed to significantly delay viral rebound in vivo.98 However, the limitation of modeling
studies focused on changes of viral reservoir measures during ART is most evident with
interventions designed to protect cells from infection, such as zinc finger nuclease induced
cleavage of CCR5,99 or modulation of immune functions, such as chimeric antigen receptor
(CAR) modified T-cells. These interventions would require an ATI to assess outcomes.
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In addition, recent data using QVOA have revealed another potentially broader limitation of
evaluating HIV within any one tissue compartment (i.e., peripheral blood). Specifically,
QVOA HIV sequences induced from isolated CD4+ T cells from PBMC and expanded ex
vivo differ, in some cases, from predominant HIV sequences detected in blood after ATI.
100–102 The explanation for this discordance remains under investigation but may reflect:
inadequate sampling depth of the peripheral reservoir to detect rare cells that may cause
rebound during ATI; distinct latent virus populations in the peripheral blood versus the
tissues from which virus rebounds;103 differences between ex vivo stimulation in the
presence of a uniform activation (e. g. mitogens or anti-CD3/28/cytokines) versus host
factors driving in vivo reactivation and viral amplification; and the absence of immune
selection pressure in static ex vivo cultures when compared to the dynamic innate, humoral,
and cell-mediated pressure influencing viral rebound in vivo.
Importantly, the onset of rebound during an ATI may be subject to sampling bias of
circulating virus alone without accounting for changes in viral persistence within mucosal
tissue compartments that house the majority of the potential reservoir as demonstrated by a
broad sampling of tissue sites for HIV viral RNA and DNA.17 These studies revealed that
98% of the viral DNA and RNA is detected in the gut and lymph node. The inability of the
field to accurately quantify changes in these tissue-resident reservoirs represents a major
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obstacle to the clinical development of approaches to shrink the reservoir. With regards to
host factors, innate (plasmacytoid dendritic cell) and adaptive variables have been noted to
predict viral rebound.104–106 Furthermore, the glycosylation signatures of plasma antibodies
and other glycoproteins on ART associate with time-to-viral-rebound and viral setpoints
upon ART cessation.107 Modeling efforts to best integrate the contribution of viral and host
surrogate measures to predict viral reservoir levels and viral rebound remain to be
developed.

Author Manuscript

Because of its high information value, we endorse the continued use of closely monitored
ATIs with defined safety-based criteria for re-starting ART in cure-directed studies.
101,108,109 Criteria on how to address ATIs in study design were addressed in a recent
consensus conference.110 It is the position of the BEAT-HIV Collaboratory that only HIV
cure-directed strategies with pre-existing evidence of a significant reduction in levels of HIV
persistence in vivo or antiviral mechanism of action in animal models, should proceed to
include an ATI in trial design in order to establish a definitive measure on the impact on HIV
control and/or reservoir size.

Conclusions
We provide the BEAT-HIV Collaboratory view for prioritization of currently available viral
measures in the design of HIV cure-directed clinical trials as follows (Figure 1):
For a 100 ml blood draw prioritize the IPDA or Q4PCR (pending validation of either assay),
followed by cell-associated RNA, then an inducible p24 assay, to be followed by measuring
levels of integrated HIV DNA.

Author Manuscript

For leukapheresis products first prioritize Q4PCR or IPDA, then cell-associated RNA,
followed with inducible p24 assay, and then confirmatory assays using either QVOA p24
SIMOA or QVOA cfRNA. We also support the TILDA when evaluating strategies aimed to
stimulate or block HIV transcription. We further support the usage of the mVOA assay as a
confirmatory test if there is a lack of replication-competent virus or HIV DNA/RNA and an
absence of an ATI in the trial design. If resources are available and the strategy is expected
to result in a subset of controllers, we support the inclusion of full-genome sequencing,
including integration site and orientation analysis in order to investigate the qualitative
potential for HIV reactivation by residual reservoirs that persists after viral control.

Author Manuscript

For tissues, prioritize the IPDA or Q4PCR, then DNA/RNAscope in situ hybridization,
followed by both cell-associated RNA and inducible p24 assay with added measures for
levels of HIV DNA, where feasible. Importantly, HIV reservoir reduction determined by any
of the aforementioned assays does not indicate potential durable viral control or eradication
without the inclusion of an ATI in trial design as no viral measurement has yet predicted a
lack of viral rebound after discontinuation of ART.
It is also important to note that “one size does not fit all” as the interpretation of viral
measures (latent or active reservoirs) on ART and how they are to be prioritized and
analyzed during HIV cure-related clinical trials may differ relative to the mechanism
anticipated for viral clearance; emerging methods for added measures of the HIV reservoirs
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using single-cell technologies; and resources available and sample availability. In
conclusion, study plans need to carefully weigh the ultimate mechanistic insight and impact
of performing any selected assay relative to the value of banking samples for future
interrogation.
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BOX 1:
BEAT-HIV Collaboratory
The BEyond Anti-retroviral Therapy Martin Delaney Collaboratory to Cure HIV-1
Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) is a consortium of
HIV researchers from leading academic research institutions working with government,
nonprofit organizations, and industry partners. BEAT-HIV Collaboratory objectives are to
advance basic cure-directed research and to conduct HIV cure-directed clinical trials
using immune-based therapies. The BEAT-HIV Collaboratory is supported by NIAID,
NIMH, NINDS, and NIDA, and The Philadelphia Foundation. For added information and
full membership go to beat-hiv.org.
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BOX 2:
Key terms
HIV reservoir:
collective term for cells infected with replication-competent HIV in blood and various
anatomical sites that persist despite long-term antiretroviral therapy and cause viral
rebound upon therapy interruption.
HIV latent reservoir:
the major component of the HIV reservoir and defined as quiescent cells carrying an
integrated copy of the viral genome that does not express viral transcripts or proteins.
HIV active reservoir:

Author Manuscript

A minor population of transcriptionally-active cells, producing HIV RNA/proteins and
possibly virions, that can be detected in people living with HIV despite long-term
therapy.
HIV proviral/provirus:
viral DNA integrated into the infected cell genome.
Near full-length HIV proviral sequencing:
Sequencing of almost the entire integrated viral genome within the infected cell genome.
Intact HIV proviruses or genomes:

Author Manuscript

HIV proviral sequence that does not contain massive deletions or mutations that can
render them defective, and therefore these intact proviruses have a high potential for
replication competency.
Defective HIV provirus:
HIV provirus that is inserted into the genome of an infected cell yet harbors mutations
and/or deletions rendering them defective and unable to replicate
Inducible HIV provirus:
HIV provirus that able to be induced to produce viral RNA, viral protein, and/or virions.
Transcriptionally-competent HIV provirus:
HIV provirus that can produce viral RNA transcripts.
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Translationally-competent HIV provirus:
HIV provirus that can produce viral proteins (such as p24).
Replication-competent HIV provirus:
HIV provirus that can produce and release virions able to replicate, resulting in
productive infection and viral amplification.
Clonal HIV proviral expansion:
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Expansion of a specific HIV provirus due to the proliferation of an HIV-infected cell
carrying this provirus.
Outgrowth assays:
Methods to induce expression/replication of HIV ex vivo using cells obtained from an
individual living with HIV (typically ART-suppressed individual).
Analytical Therapy Interruption (ATI):
cessation of antiretroviral therapy followed by monitoring viral rebound.
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Figure 1.
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The collective view of the BEAT-HIV Collaboratory on the priority for measuring HIV
reservoir size, in blood and tissues, during HIV cure-related clinical trials.
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Frequencies of cells harboring
replication-competent HIV that can be
induced ex vivo to produce infectious
virus.

Quantitative Viral Outgrowth
assay (QVOA).3,20,21,23,111

Advantages
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Less labor-intensive and more consistent
compared to the traditional QVOA; clade
independent.
Provides additional insights on the
qualitative nature of HIV proviral DNA.

Eliminates 97% of defective proviruses and
is predicted to overestimate the size of the
latent reservoir by only ~ 1.5 fold; simple,
medium cost, and fast compared to
traditional QVOA.
Estimates levels of replication-competent
virus; results are verified by sequencing;
sensitive.

Measures the levels of genetically-intact
proviruses in a definitive manner.
Cost-effective; simple compared to singlegenome sequencing.
Efficiently reports locations of integration
sites, and associations of insertional
mutagenesis and clonal expansion
Investigate chromosomal positioning and
integration site features of intact HIV-1
proviruses.

Frequencies of cells harboring
replication-competent HIV that can be
induced ex vivo to produce infectious
virus.
Frequency of cells encoding HIV
proviral DNA that can be induced ex
vivo, as well as genetic and potentially
phenotypic characterization of latent
viruses.
Frequency of cells encoding intact and
defective proviral HIV DNA.

Frequency of cells encoding intact and
defective proviral HIV DNA
confirmed by sequencing.

Levels and genetic characteristics of
genetically-intact proviruses.
Could measure levels of geneticallyintact proviruses.
Distributions of integration HIV
proviruses, with linked information on
clonal abundance
Individual proviral sequences and
corresponding chromosomal
integration site.

The qualitative and
quantitative viral outgrowth
assay (Q2VOA).24

Intact proviral DNA assay
(IPDA): HIV DNA by digital
droplet PCR targeting multiple
regions of proviral DNA to
exclude deleted and
hypermutated proviruses.27

HIV DNA by limiting dilution
four-probe qPCR assay
followed by sequence
verification of reactions
positive for two or more probes
(Q4PCR).28

Near full-length individual
proviral sequencing (FLIPSeq).20,25

Proviral ultra-deep sequencing.

High throughput integration
site sequence analysis.114115

Matched integration site and
proviral sequencing (MIP-Seq).

Has been regarded as the definitive assay to
measure the size of the replicationcompetent HIV reservoir; clade independent.

Modified QVOA using cell lines
supporting HIV replication.112

39

113

Drawbacks

Technically complex and cost-intensive.

Requires specialized expertise; costintensive; requires workable numbers of
proviruses to analyze in samples

Potential template resampling and PCR
errors/bias; cost-intensive; clade dependent.

Time-consuming and labor-intensive; costintensive; requires custom design of primers.

Lower throughput and more timeconsuming, and labor-intensive compared to
IPDA; cost-intensive; clade dependent; does
not measure the inducibility of the
proviruses; does not provide absolute
quantification.

Sequence polymorphisms could preclude
amplification in some patients; alternative
primers/probes needed; clade-dependent;
does not measure the inducibility of the
proviruses.

Underestimates the size of the replicationcompetent virus as it misses replicationcompetent non-induced proviruses, similar to
traditional QVOA. Labor, time, and costintensive; the sequencing part of the assay
could be clade dependent.

Underestimates the size of replicationcompetent HIV reservoir; requires a large
number of cells; cost-intensive.

Underestimates the size of the replicationcompetent HIV reservoir; requires a large
number of cells; time-consuming and laborintensive; cost-intensive.

Assays measuring levels of replication-competent virus or intact HIV genomes

What it measures?

Assay
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Current viral measurements and strategies to estimate HIV reservoir size.

No stimulation or
expansion.

No stimulation or
expansion.

No stimulation or
expansion.

No stimulation or
expansion.

No stimulation or
expansion.

No stimulation or
expansion.

ex vivo stimulation
followed by expansion.

ex vivo stimulation
followed by expansion.

ex vivo stimulation
followed by expansion.

Involves stimulation
and/or expansion?
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Sensitive; simple; fast; relatively costeffective; requires relatively few cells;
application across sample types;
measurement of productively expressing
“active” and “inducible” reservoirs; closer to
replication competence when compared to
measuring HIV transcripts; biologically
relevant target for immune response and
immune-based interventional approaches.
Simpler, faster, and requires fewer cells
compared to QVOA; can be useful in
measuring the response to LRAs ex vivo.

Single-cell insights of HIV transcription
and/or translation and phenotypic
characterization of individual cells; clade
independent; relatively cost-effective.

Productive HIV p24 expression in the
presence or absence of ex-vivo
stimulation.

The number of cells harboring
transcriptionally reactivatable HIV
tat/rev msRNA.

Measures the frequency of cells
undergoing HIV transcription and/or
translation upon stimulation at the
single-cell level.

Cell-associated p24 protein
quantification. 116

Induction-based viral RNA
reactivation assays (including
TILDA).57,66,117

Single-cell analysis of inducible
virus (including FISH/flow). 56

Do not measure replication competence.

Measure inducible levels of HIV transcripts
(transcriptional competence) without
distinction of defective or replicationcompetent (replication competence); costintensive; semi-labor intensive unless
automated.

May overestimate reservoir size as detects
translation-competent and replicationcompetent provirus rather than the
replication-competent virus.

Can detect cells infected with a replicationincompetent virus that is able to produce
viral RNA or protein; Semi-labor intensive
unless automated; cost-intensive.

Fast, relatively cost-effective, and sensitive;
cell-sparing; application across sample
types; Different HIV transcripts can be
measured to indicate the degree of HIV
transcriptional activity; may provide a
surrogate measure for reservoir size as levels
of HIV RNA during ART predict time to
viral rebound upon treatment cessation.
Fast, cost-effective, and sensitive; cellsparing, application across sample types;
most available assays span across different
clades.
Visualize and phenotypically characterize
infected cells in tissues; allow for a better
understanding of the anatomical distribution

Levels of HIV transcripts (a surrogate
of transcription-competent cellular
HIV) without distinction of defective,
translation-competent, or replicationcompetent.

Levels of selected regions of total,
integrated, or circular HIV DNA
measure without distinction of
defective or replication-competent
provirus.
Cellular location and levels of HIV
sequences associated with integration
(DNA) or transcription (RNA) without

Cell-associated HIV RNA by
real-time or droplet digital
PCR.53,61–64,75,93,118

HIV DNA by real-time PCR or
droplet digital PCR.

In situ hybridization-based
assays, e.g., DNAscope and
RNAscope.53,70,71

Do not measure replication competence;
clade dependent.

Vastly overestimates the size of the HIV
reservoir, as only a small fraction of HIV
genomes is able to be reactivated upon ex
vivo stimulation to produce replicationcompetent virus.

Overestimates the size of the latent HIV
reservoir. Doesn’t measure translation- or
replication-competence; clade dependent.

Assays measuring constitutive levels of HIV DNA and cell-associated HIV RNA

Simple, fast, and requires fewer cells
compared to QVOA; detects transcriptionalcompetent and translation-competent virus.

Frequencies of cells harboring
transcription-competent and
translation-competent HIV that can be
induced ex vivo.

Modified QVOA using ultrasensitive readouts (including
QVOA p24 SIMOA and QVOA
cfRNA).57–59

34,53,72–76,79,81,93

Multiple animals are required per sample if a
quantitative value is needed; needs a large
number of cells; cost-intensive.

Drawbacks

Assays measuring inducible translationally- or transcriptionally-competent virus

Can detect low levels of latent infection;
clade independent.

Presence/absence of replicationcompetent virus within the number of
cells/tissues tested.
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Murine viral outgrowth assay
(mVOA).33

Author Manuscript
Advantages

Author Manuscript

What it measures?

No stimulation or
expansion.

No stimulation or
expansion.

No stimulation or
expansion.

Can be done without
stimulation but usually
done with short ex-vivo
stimulation but no
expansion.

short ex-vivo
stimulation but no
expansion.

Can be done without
stimulation but usually
done with short ex vivo
stimulation but no
expansion.

ex vivo stimulation
followed by expansion
(unless done in the
presence of ART).

In vivo expansion.

Involves stimulation
and/or expansion?
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Assay
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Could represent virus release from stable
reservoirs, including these in tissues;
relatively cost-effective.

Determines the duration of HIV remission
upon the cessation of ART. It is the most
clinically relevant measure of the impact of
interventions on the total body burden of
HIV infection.

The release of HIV particles in vivo
during ART, without distinction of
tissue origin.

Systemic virus replication in vivo after
ART-cessation, without distinction of
tissue origin.

Ultra-sensitive residual
viremia.67–69

Common strategy to test for
viral burden on ART yet not an
“Assay,” included
here for comparison only:
Analytical Treatment
Interruptions (ATI).98,110

Assays measure the in vivo burden of HIV reservoirs

of infected cells in vivo; cost-effective; near
sensitivity to qRT-PCR.

distinction of defective or replicationcompetent.
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Advantages

Potential clinical risks to individuals
stopping therapy and to their partners;
clinically demanding; substantial reservoir
reductions are needed to produce significant
delays in viral rebound, so unlikely any
current interventions could result in a
significant delay in viral rebound. Effort and
monitoring cost-intensive

Requires large volumes of plasma or body
fluid; limited dynamic range; the relationship
between the HIV reservoir and low-level
viremia during ART viremia is unclear;
clade dependent.

Drawbacks
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What it measures?

In vivo expansion.

No stimulation or
expansion.

Involves stimulation
and/or expansion?
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Assay

Abdel-Mohsen et al.
Page 24

Nat Med. Author manuscript; available in PMC 2020 November 30.

